The stock of GlycoMimetics Inc (GLYC) has gone up by 2.92% for the week, with a -9.98% drop in the past month and a 16.43% rise in the past quarter. The volatility ratio for the week is 5.99%, and the volatility levels for the past 30 days are 8.89% for GLYC. The simple moving average for the past 20 days is 1.59% for GLYC’s stock, with a 7.75% simple moving average for the past 200 days.
Is It Worth Investing in GlycoMimetics Inc (NASDAQ: GLYC) Right Now?
Additionally, the 36-month beta value for GLYC is 1.63. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for GLYC is 56.10M and currently, short sellers hold a 5.11% ratio of that float. The average trading volume of GLYC on March 21, 2025 was 1.47M shares.
GLYC) stock’s latest price update
GlycoMimetics Inc (NASDAQ: GLYC)’s stock price has dropped by 0.00 in relation to previous closing price of 0.27. Nevertheless, the company has seen a gain of 2.92% in its stock price over the last five trading days. prnewswire.com reported 2025-03-05 that NEW YORK, March 5, 2025 /PRNewswire/ — Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Chimerix, Inc. (NASDAQ: CMRX)’s sale to Jazz Pharmaceuticals plc for $8.55 per share in cash. If you are a Chimerix shareholder, click here to learn more about your rights and options.
Analysts’ Opinion of GLYC
CapitalOne gave a rating of “Overweight” to GLYC, setting the target price at $12 in the report published on December 22nd of the previous year.
GLYC Trading at 0.38% from the 50-Day Moving Average
After a stumble in the market that brought GLYC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -91.47% of loss for the given period.
Volatility was left at 8.89%, however, over the last 30 days, the volatility rate increased by 5.99%, as shares sank -9.09% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -5.63% lower at present.
During the last 5 trading sessions, GLYC rose by +1.67%, which changed the moving average for the period of 200-days by -2.05% in comparison to the 20-day moving average, which settled at $0.2670. In addition, GlycoMimetics Inc saw 9.00% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at GLYC starting from Invus Public Equities, L.P., who sale 260,873 shares at the price of $0.19 back on Aug 08 ’24. After this action, Invus Public Equities, L.P. now owns 6,317,565 shares of GlycoMimetics Inc, valued at $50,009 using the latest closing price.
Invus Public Equities, L.P., the 10% Owner of GlycoMimetics Inc, sale 61,488 shares at $0.18 during a trade that took place back on Aug 07 ’24, which means that Invus Public Equities, L.P. is holding 6,578,438 shares at $11,197 based on the most recent closing price.
Stock Fundamentals for GLYC
The total capital return value is set at -7.54. Equity return is now at value -173.25, with -134.30 for asset returns.
Based on GlycoMimetics Inc (GLYC), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -465.23.
Currently, EBITDA for the company is -40.04 billion with net debt to EBITDA at 0.33. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.92.
Conclusion
In conclusion, GlycoMimetics Inc (GLYC) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
